linjc16/ctgov huggingface dataset:
Digital Versus Conventional Altered Cast Techniques For Constructing Mandibular Distal Extension Removable Partial Dentures Using Digitally Fabricated Frameworks: Alveolar Bone Height Changes

Study Overview
=================
Brief Summary
-----------------
This clinical study compares between digital and conventional removable partial dentures' construction techniques using digitally approaches regarding their effect on bone height changes of abutment teeth and residual ridge.

Official Title
-----------------
Digital Versus Conventional Altered Cast Techniques For Constructing Mandibular Distal Extension Removable Partial Dentures Using Digitally Fabricated Frameworks: Alveolar Bone Height Changes

Conditions
-----------------
Denture, Partial, Removable

Intervention / Treatment
-----------------
* Other: Removable Partial Denture Construction


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients having completely edentulous maxilla and class I Kennedy mandible. Sufficient (not less than 15 mm) restorative space must be available (from the mucosa covering the crest of the residual ridge to proposed occlusal plane). This will be detected by a tentative jaw relation. All patients are of angel's class I maxillo-mandibular relationships Abutment teeth must meet certain requirements : A. Abutment teeth should be healthy with good periodontal and bone support. B. should not show advanced destructions. C. should not show a pronounced degree of mobility or advanced gingival recession. D. Crown Root Ratio for an abutment is 1:2 Exclusion Criteria: Sever undercuts or concavities on the buccal or lingual sides of the ridge. Systemic diseases that may affect bone changes such as diabetes and osteoporosis. History of radiotherapy in the head and neck region. Crown Root Ratio for an abutment is 1:1.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Group A<br>Digitally obtained altered cast for construction of mandibular free end saddle removable partial denture | Other: Removable Partial Denture Construction<br>* Construction of class I Removable partial denture by digital workflow<br>|
| Active Comparator: Group B<br>Conventionally obtained altered cast for construction of mandibular free end saddle removable partial denture | Other: Removable Partial Denture Construction<br>* Construction of class I Removable partial denture by digital workflow<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Alveolar Bone Height Changes | Alveolar bone height changes of abutment teeth and residual ridge. | one year |
Incidence Rate and Risk Factors of Malnutrition in ICU

Study Overview
=================
Brief Summary
-----------------
To assess the incidence of malnutrition in surgical Intensive Care Unit by NUTRIC score. To determine the different risk factors of malnutrition

Detailed Description
-----------------
To assess the incidence of malnutrition in surgical Intensive Care Unit by NUTRIC score. To determine the different risk factors of malnutrition by assessment of the type of nutrition, caloric adequacy, and actual caloric intake, laboratory Investigations twice weekly

Official Title
-----------------
Incidence Rate and Risk Factors of Malnutrition in Patients Admitted to Surgical Intensive Care Unit

Conditions
-----------------
Malnutrition

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients who will be admitted to surgical ICU. Both sexes. Exclusion Criteria: • Referral from another hospital or other ICU

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assess incidence rate of malnutrition in ICU | Assessment of nutrition state by (NUTRIC) Score on admission and weekly until patient discharge or death | From the date of randomization until the date of ICU discharge or death, assessed up to 4 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation of risk factors with malnutrition in ICU | correlation of risk factors such as: age, comorbidities, and sepsis with malnutrition | From the date of randomization until the date of ICU discharge or death, assessed up to 4 months |
Reduction Nymphoplasty: Assessment of the Impact on Sexuality, Self-Esteem and Screening for Dysmorphophobia

Study Overview
=================
Brief Summary
-----------------
Reduction nymphoplasty is the treatment of benign hyperplasia of the labia minora. This surgery is indicated in the event of functional, aesthetic or sexual discomfort. There has been a growing demand for this surgery over the past twenty years. It is necessary to remain vigilant because a request for cosmetic surgery can also be part of an obsession with body dysmorphism, former dysmorphophobia. Investigators wish to study the postoperative results concerning sexuality, self-esteem and obsession with body dysmorphia in a cohort of patients followed prospectively and at more than 3 years postoperatively.

Official Title
-----------------
Reduction Nymphoplasty: Assessment of the Impact on Sexuality, Self-Esteem and Screening for Dysmorphophobia

Conditions
-----------------
Plastic Surgery

Intervention / Treatment
-----------------
* Other: FSFI
* Other: BES


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients informed of the objectives of the study and its progress, Exclusion Criteria: Patients in a period of exclusion determined by another study. Patients under judicial safeguard, guardianship or curatorship. Patients for whom it is impossible to give informed information.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: FSFI|Female Sexual Function Index questionnaire|
|Other: BES|Body Esteem Scale questionnaire|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Female Sexual Function Index (FSFI) | Questionnaire on the evolution of sexuality. FSFI consists of 19 questions assessing 6 domains: sexual desire, arousal, lubrication, orgasm, sexual satisfaction and pain. It is based on the sexuality of the last 4 weeks. The questions report a score ranging from 0 or 1 to 5 and a different coefficient is assigned to each domain. The sum of these results constitutes the final score, between 2 and 32 with the threshold value defining an alteration of sexuality below 26.5/32. | Change from Baseline 3 yers after surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Body Esteem Scale (BES) | Self-esteem questionnaire BES is composed of 23 questions, rated on a 5-point Likert scale (never, rarely, sometimes, often and always) and divided into 3 items corresponding to different dimensions of self-esteem: appearance, attribution and weight. The score is between 23 and 115, and the higher it is, the higher the body esteem and the appearance evaluated positively | Change from Baseline 3 yers after surgery |
Juvenile Systemic Sclerosis, a Retrospective Epidemiological Study on a French Cohort

Study Overview
=================
Brief Summary
-----------------
Scleroderma is an inflammatory attack of the vessels leading to localized or multisystemic sclerosis. It is a rare autoimmune pathology in pediatrics. The incidence in pediatrics is very low (about 4 per million according to an American) and therefore the data on the pathology very poor, especially on the therapeutic level. The proposed immunosuppressive treatments are extrapolated from data in adults. The evolution of connectivity does not seem quite identical to the evolution of adult scleroderma, adaptation of treatments seems judicious. However, data on the evolution under therapy in children are still poor. Complications related to the pathology, iatrogeny and diagnostic delay are the first causes of mortality from this pathology and deserve to be studied and if possible avoided. The main hypothesis of the research being to bring together the experiences of the various reference and competence centers in France concerning the clinical presentation, management and follow-up of children with systemic sclerosis.

Official Title
-----------------
Uvenile Systemic Sclerosis, a Retrospective Epidemiological Study on a French Cohort

Conditions
-----------------
Juvenile Systemic Sclerosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Minor subject (<18 years old) Diagnosis of systemic sclerosis between 01/01/2012 and 30/06/2022. Subject (and/or his parental authority) who has not expressed, after being informed, his opposition to the reuse of his data for the purposes of this research. Exclusion criteria: - Subject (or his parents) having expressed his (their) opposition to participating in the study

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The therapeutic response was evaluated by the EULAR DAS 28 -CRP |  | at 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Systemic Sclerosis, Juvenile Systemic Sclerosis, Immunosuppressive treatments
First in Human, Single Ascending Dose Study

Study Overview
=================
Brief Summary
-----------------
The goal of this study is to evaluate the safety and tolerability of single ascending oral doses of INV-101 in healthy adult subjects.

Official Title
-----------------
A First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of INV-101 Administered Orally to Healthy Adult Subjects

Conditions
-----------------
Ulcerative Colitis

Intervention / Treatment
-----------------
* Drug: INV-101


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy, adult, male or female (of non-childbearing potential only), 19-55 years of age, inclusive, at the screening visit. Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m2 at the screening visit. Exclusion Criteria: Mentally or legally incapacitated or had significant emotional problems at the time of the screening visit or expected during the conduct of the study. History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee.

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: A<br>Dose A | Drug: INV-101<br>* subjects will be randomized 3:1 ratio<br>|
| Placebo Comparator: B<br>Dose B | Drug: INV-101<br>* subjects will be randomized 3:1 ratio<br>|
| Placebo Comparator: C<br>Dose C | Drug: INV-101<br>* subjects will be randomized 3:1 ratio<br>|
| Placebo Comparator: D<br>Dose D | Drug: INV-101<br>* subjects will be randomized 3:1 ratio<br>|
| Placebo Comparator: E<br>Dose E | Drug: INV-101<br>* subjects will be randomized 3:1 ratio<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AE | Number and severity of treatment-emergent adverse events (TEAEs) following single oral doses of INV-101 and placebo. | 2 weeks |
Fascia Iliaca Block Versus Intravenous Dexmedetomidine and Ketamine for Positioning Fracture Femur

Study Overview
=================
Brief Summary
-----------------
Proximal femur fractures are one of the commonest fractures especially in the elderly population. Early surgical fixation is the best analgesic for associated pain. Spinal anesthesia has been favored by many anesthesiologists due to the simplicity of the technique, the better analgesic profile, and the lower incidence of complications like delirium and thromboembolic events. However, severe pain, encountered during positioning for spinal anesthesia, can complicate the technique and worsen the patient experience. the study aim to compare the analgesic effect of intravenous dexmedetomidine and fascia iliaca block preoperatively to assist positioning patients for performance of spinal anesthesia.

Official Title
-----------------
Ultrasound Guided Fascia Iliaca Block Versus Intravenous Dexmedetomidine and Ketamine for Positioning Fracture Femur Patients During Spinal Anesthesia: Randomized Comparison Study

Conditions
-----------------
Pain, Analgesia

Intervention / Treatment
-----------------
* Device: ultrasound guided facia iliaca block
* Drug: Intravenous drug


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged 18-60 years. Hip fractures Both sexes. Exclusion Criteria: Patient refusal Allergy to local anesthetics Bleeding diathesis or history of anticoagulant use. impaired cognition or dementia . Infection of the skin at the site of needle punctures area multiple fractures Any previous analgesic administration during the last 12 hours

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: facia iliaca block<br> | Device: ultrasound guided facia iliaca block<br>* Patient will received ultrasound guided fascia iliaca block by 20 ml Bupivacaine 0,25% .<br>|
| Experimental: Precedex and ketamine<br> | Drug: Intravenous drug<br>* Patient will received intravenous injection of precedex 0.25mic/Kg and ketamine 0,2 mg/kg .<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Behavioral pain scale | 0 = calm, 1 = facial grimacing, 2 = moaning, 3 = screaming, and 4 = unable to proceed because of restlessness or agitation | during spinal anesthesia | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of patient's position | 0 = poor hip flexion, 1 = satisfactory hip flexion, 2 = good hip flexion, and 3 = optimal hip flexion | before spinal anesthesia |
Using Point-of-Care-Ultrasound (POCUS) to Assess Gastric Contents Among Fasting Pre-operative Patients Taking GLP-1 Agonists.

Study Overview
=================
Brief Summary
-----------------
Given the increased prescription of GLP-1 agonists for both diabetes and obesity management and the implications of the proposed delayed gastric emptying in the setting of an anesthetic, it is critical to determine if patients taking GLP-1 agonists have an increased rate of delayed gastric emptying. The purpose of this prospective gastric ultrasound evaluation of pre-operative patients is to determine the incidence of a full stomach despite a standard pre-operative fasting period.

Official Title
-----------------
Using Point-of-Care-Ultrasound (POCUS) to Assess Gastric Contents Among Fasting Pre-operative Patients Taking GLP-1 Agonists.

Conditions
-----------------
Delayed Gastric Emptying, Gastroparesis

Intervention / Treatment
-----------------
* Diagnostic Test: gastric ultrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: GLP-1 agonist use within previous 30 days Appropriately fasted per standard guidelines Exclusion Criteria: History of gastric surgery / gastric volume reduction Critical illness Inability to provide informed consent <18 years of age

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| GLP-1 agonists<br>Pre-operative gastric ultrasound to evaluate for retained gastric contents in appropriately fasted patients | Diagnostic Test: gastric ultrasound<br>* Utilize POC gastric ultrasound to identify the presence of retained gastric contents.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retained gastric contents | Presence of retained gastric contents, either liquid or solid | At time of pre-operative assessment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
GLP-1 agonists, retained gastric contents, glucagon-like peptide receptor-1 agonists, perioperative
Brain Lesion and Visuospatial Impairment in CP Child

Study Overview
=================
Brief Summary
-----------------
Children with cerebral palsy (CP) show varying degrees of motor impairment and movement disorders whose perceptive-visual contribution has yet to be established. The literature reports that children with CP have more frequent neuro-visual disorders. The link between the location and size of the brain lesion and neurovisual symptomatology has yet to be explored. In this retrospective clinical data study, we will investigate in children with PC whether there is an anatomo-clinical correlation between visuo-spatial disorders is the brain injury of interest to the dorsal visual pathway. We will explore the volume of grey and white matter parietal involvement. To test visuo-spatial disorders, we will use the PVSE (Visuo-Spatial Elementary Perception) test which does not require motor skills or language and is therefore suitable for children with a PC. This test will make it possible to better identify the deficit or deficits in order to adapt an early remediation. It could serve as a reference for comparing several pathologies/etiologies.

Official Title
-----------------
Visuo-spatial Profile in Children With Cerebral Palsy Born at Term or Not and Anatomical Correlation

Conditions
-----------------
Children With Cerebral Palsy

Intervention / Treatment
-----------------
* Diagnostic Test: PVSE Test
* Other: Cerebral MRI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female aged 4 to 18 yo With a CP diagnosis With PVSE test completion during his/her regular follow-up With a cerebral MRI scan during his/her regular follow-up Exclusion Criteria: - With an incomplete PVSE test or whose interpretation was deemed unreliable by the rater

Ages Eligible for Study
-----------------
Minimum Age: 4 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| CP child<br> | Diagnostic Test: PVSE Test<br>* Completion of the PVSE test<br>Other: Cerebral MRI<br>* Cerebral MRI scan<br>|
| CP child with a PVSE test and a cerebral MRI performed during his/her follow-up<br> | Diagnostic Test: PVSE Test<br>* Completion of the PVSE test<br>Other: Cerebral MRI<br>* Cerebral MRI scan<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PVSE test results: total score and 8 sub-scores (length perception, size perception, angle comparison, midline localization, position perception, position selection, occipital score and parietal score.) | Using normative values of PVSE test, we assess pathological measure inferior outlier limits and subnormal measure below the lower quartile limit | At the inclusion | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cerebral Palsy, child, visuo-spatial disorder, brain lesion
Middle East African Registry Women CardioVascular Disease

Study Overview
=================
Brief Summary
-----------------
The MEA cardiology societies have joined forces to tackle the issue by establishing a tangible real-world data registry in every MEA country. This endeavor has resulted in the development of a multicenter registry called MEA-WCVD, which is being sponsored by each national cardiology society from participating countries. All data gathered will be consolidated into a singular registry for thorough analysis. Country specific analysis will be performed.

Official Title
-----------------
Middle East African Registry Women CardioVascular Disease

Conditions
-----------------
Heart Failure, Atrial Fibrillation, Valvular Heart Disease, Ischemic Heart Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All incomers in Cardiovascular (CV) diseases in hospital or out hospital facilities with one of the 4 diagnosis (Heart Failure (HF), Atrial fibrillation (AF), Valvular Heart disease (VHD), ischemic heart disease (IHD) Age over 18 years old Men and Women Signature of consent form Exclusion Criteria: Patients with diseases other than the 4 previously mentioned in inclusion criteria

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cardiovascular diseases care management in women will be compared to men in MEA countries according to current practice guidelines |  | 2 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identify inequalities between both genders in terms of: • Healthcare insurance • Incomes • Access to healthcare |  | 2 months |